A clinical study of SKB-518 in USA
Latest Information Update: 05 May 2025
At a glance
- Drugs SKB 518 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 05 May 2025 New trial record
- 21 Apr 2025 According to a Sichuan Kelun Biotech Biopharmaceutical media release, the IND for SKB518 has been cleared by the USFDA.